Levosimendan Kabi

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer presented as a sterile intravenous solution for infusion use. It increases cardiac contractility and promotes vasodilation, making it suitable for the treatment of acute decompensated heart failure in adult patients.

GNH USA supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Levosimendan is used in the management of acute heart failure, acting as an inotropic and vasodilating agent.

- Acute decompensated heart failure: improves cardiac output and reduces symptoms of low perfusion. - Acute decompensated heart failure: decreases pulmonary capillary wedge pressure, helping relieve congestion. - Acute decompensated heart failure: facilitates weaning from mechanical ventilation or circulatory support in stabilized patients.

Levosimendan may be associated with several adverse reactions, which are classified by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Hypotension: transient drop in blood pressure. - Arrhythmias: occasional ventricular ectopy. - Flushing: warm sensation with skin reddening. - Dizziness: related to blood pressure changes.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Life‑threatening arrhythmias: ventricular tachycardia or fibrillation. - Allergic reactions: anaphylaxis or severe skin rash.

Levosimendan requires careful monitoring and specific safety measures before and during therapy.

- Cardiovascular monitoring: continuous ECG and blood pressure monitoring is required during infusion. - Electrolyte balance: correct potassium and magnesium levels before administration. - Renal function: assess renal function as dosage may need adjustment in severe impairment. - Hepatic impairment: use with caution in patients with significant liver disease. - Concomitant vasodilators: monitor for excessive hypotension when combined with other vasodilators. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations of levosimendan. - Concurrent use with other inotropes (e.g., dobutamine): can cause excessive cardiac stimulation. - Nitrates or phosphodiesterase‑5 inhibitors: risk of profound hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effects; monitor blood pressure. - Beta‑blockers: may blunt the inotropic response; adjust dosing as needed. - Anticoagulants: monitor coagulation parameters as levosimendan can affect platelet function.